Los Angeles - Cutaneous atrophy, the bane of topical corticosteroid treatment, may have met its match in a thyroid hormone analogue, according to Jan Faergemann, M.D., Ph.D.
Insights Into Clear Health’s Low-Dose Microdose Accutane Protocol For Mild Acne
The Cutaneous Connection: A Reminder of Patient Impact
Understanding Buy and Bill for Medical Dermatology: A Win-Win
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
New Eblasakimab Data Shows Promise for Patients With AD and Inadequate Response to Dupilumab
Patients With Vitiligo Have Decreased Risk of Subsequent Pulmonary Embolism, Peripheral Vascular Disease